These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17490557)

  • 21. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
    Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
    Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Management of chronic myeloid leukemia].
    Kubuki Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of lower dose of imatinib to CML patients.
    Horikoshi A; Takei K; Sawada S
    Leuk Res; 2003 Dec; 27(12):1167. PubMed ID: 12921957
    [No Abstract]   [Full Text] [Related]  

  • 32. Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells.
    Palamà IE; Leporatti S; de Luca E; Di Renzo N; Maffia M; Gambacorti-Passerini C; Rinaldi R; Gigli G; Cingolani R; Coluccia AM
    Nanomedicine (Lond); 2010 Apr; 5(3):419-31. PubMed ID: 20394535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
    Deshmukh C; Saikia T; Bakshi A; Amare-Kadam P; Baisane C; Parikh P
    J Assoc Physicians India; 2005 Apr; 53():291-5. PubMed ID: 15987013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
    Zonder JA; Pemberton P; Brandt H; Mohamed AN; Schiffer CA
    Clin Cancer Res; 2003 Jun; 9(6):2092-7. PubMed ID: 12796373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
    Okabe S; Tauchi T; Ishii Y; Akahane D; Nunoda K; Honda S; Takaku T; Ohyashiki K
    Int J Hematol; 2007 Feb; 85(2):173-4. PubMed ID: 17321998
    [No Abstract]   [Full Text] [Related]  

  • 36. Chronic myeloid leukemia: where do we go now?
    Cortés JE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S374-5. PubMed ID: 20007105
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
    Fischer T; Reifenrath C; Hess GR; Corsetti MT; Kreil S; Beck J; Meinhardt P; Beltrami G; Schuch B; Gschaidmeier H; Hehlmann R; Hochhaus A; Carella A; Huber C
    Leukemia; 2002 Jul; 16(7):1220-8. PubMed ID: 12094246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
    Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
    Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
    Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M;
    J Clin Oncol; 2008 Jan; 26(1):106-11. PubMed ID: 18165644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.